A Phase II Study (ARCHER 1042) to Evaluate Prophylactic Treatment of Dacomitinib-induced Dermatologic and Gastrointestinal Adverse Events in Advanced Non-Small-Cell Lung Cancer

The randomized phase II study ARCHER 1042 explored the impact of prophylactic treatment on select dermatologic and gastrointestinal adverse events (AE) of interest and patient-reported outcomes. Doxycycline reduced the incidence of grade ≥2 select dermatologic AEs of interest by 50% (p=0.016). Both doxycycline and alclometasone reduced the negative impact in patient-reported dermatologic AEs.

from Cancer via ola Kala on Inoreader http://ift.tt/25PZBV8
via IFTTT